| Literature DB >> 35745554 |
Se-Min Hwang1,2,3,4, Yoomi Jung5, Haesook Seo6.
Abstract
There is a paucity of data regarding the differentiating characteristics of patients who were infected with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by fomites around the world. We conducted an event-based outbreak investigation, involving 795 public officers and 277 assistant staff, in the Ministry of Oceans and Fisheries (MOF) or the same building from March 2 to March 18, 2020. The SARS-CoV-2 patients were found to have more frequently touched fomites and used public toilets than those who were tested negative for the virus (cOR, 24.38; 95% CI, 4.95-120.01). Symptoms such as coughing and loss of taste and smell were more frequently found in the office-cleaner group than in the public-officer group. The SARS-CoV-2 office-cleaner patients were more likely to have a high RdRp(Ct) value of PCR (median: 34.17 vs. 24.99; p = 0.035) and E(Ct) value of PCR (median: 32.30 vs. 24.74; p = 0.045). All office cleaner patients (100%) had a ground glass opacity in both lobes. Regarding segmental lung involvement of CT, two patients (100%) had a lesion in the right middle lobe, which invaded the whole lobe later. This implies that the fomite might be a selective risk factor of SARS-CoV-2 infection.Entities:
Keywords: COVID-19; SARS-CoV-2; diagnostics; fomites; risk factors
Year: 2022 PMID: 35745554 PMCID: PMC9228738 DOI: 10.3390/pathogens11060700
Source DB: PubMed Journal: Pathogens ISSN: 2076-0817
Figure 1Study population.
Figure 2Epidemic curve of SARS-CoV-2 patients with laboratory-confirmed cases of MOF in South Korea.
Epidemic characteristics of the COVID-19 (+) patients and COVID-19 (−) contactors *.
| COVID-19 (+): | COVID-19 (−): | OR | 95% CI | ||||
|---|---|---|---|---|---|---|---|
| Yes | No | Yes | No | ||||
| Demographics | |||||||
| Age, median (range) † | 45 (26–59) | 41 (20–58) | 0.383 | ||||
| Male | 7 (63.6) | 4 (36.4) | 239 (72.4) | 91 (27.6) | 0.507 | 0.67 | 0.191–2.330 |
| Contact risk factor by COVID-19 (+) | |||||||
| Contact interval < 2 m | 5 (45.5) | 6 (54.5) | 202 (61.2) | 128 (38.8) | 0.352 | 0.53 | 0.158–1.766 |
| No mask | 7 (63.6) | 4 (36.4) | 180 (54.5) | 150 (45.5) | 0.551 | 1.46 | 0.419–5.077 |
| Same office room | 4 (36.4) | 7 (63.6) | 140 (42.4) | 190 (57.6) | 0.766 | 0.78 | 0.223–2.701 |
| Physical contact (ex. Handshake, etc.) | 1 (9.1) | 10 (90.9) | 10 (3.0) | 320 (97.0) | 0.307 | 3.20 | 0.373–27.467 |
| Night or special duty | 0 (0) | 11 (100.0) | 55 (16.7) | 275 (83.3) | 0.223 | ||
| Meeting of meal or coffee | 2 (18.2) | 9 (81.8) | 49 (14.8) | 281 (85.2) | 0.672 | 1.27 | 0.267–6.076 |
| Conference or conversation | 3 (27.3) | 8 (72.7) | 59 (17.9) | 271 (82.1) | 0.428 | 1.72 | 0.444–6.687 |
| Same place of smoking | 0 (0) | 11 (100) | 3 (0.9) | 327 (99.1) | 1.000 | ||
| Sharing of fomites and toilet | 3 (27.3) | 8 (72.7) | 5 (1.5) | 325 (98.5) | 0.001 | 24.38 | 4.951–120.010 |
| Sharing of elevator | 1 (9.1) | 10 (90.9) | 6 (1.8) | 324 (98.2) | 0.207 | 5.4 | 0.593–49.154 |
| Meeting rooftop or corridor | 1 (9.1) | 10 (90.9) | 5 (1.5) | 325 (98.5) | 0.180 | 6.5 | 0.694–60.895 |
| Sharing car | 0 (0) | 11 (100) | 8 (2.4) | 322 (97.6) | 1.000 | 0.97 | 0.948–0.986 |
| Contact time (minute): median (range) ** | 25.5 (1–50) | 15 (0.05–180) | 0.642 | ||||
*: Number of COVID-19 patients (11 confirmed case) and contactors were 341, including 339 public officer (17–18 March 2020) and 2 office cleaners, who answered for the contact risk factor of COVID-19 (11 June 2020). **: χ2 test and Fisher’s exact test (p-value < 0.05), †: Mann–Whitney test (p-value < 0.05).
Figure 3Clinical courses and outcomes of SARS-CoV-2 office cleaner patients.
Characteristics of the COVID-19 (+) participants at admission. (N = 30).
| Office Cleaner: | Public Officer: | OR | 95% CI | ||||
|---|---|---|---|---|---|---|---|
| Yes | No | Yes | No | ||||
| Demographics ( | |||||||
| Age, median (range) ** | 58.5 (58–59) | 45.5 (26–57) | 0.845 | ||||
| Male | 1 (50.0) | 1 (50.0) | 22 (78.6) | 6 (21.4) | 0.418 | 0.27 | 0.015–5.032 |
| Symptoms ( | |||||||
| Fever | 1 (50.0) | 1 (50.0) | 9 (32.1) | 19 (67.9) | 1.000 | 2.11 | 0.118–37.72 |
| Cough | 2 (100) | 0 (0) | 13 (46.4) | 15 (53.6) | 0.483 | ||
| Sputum | 1 (50.0) | 1 (50.0) | 4 (14.3) | 24 (85.7) | 0.310 | 6.00 | 0.309–116.61 |
| Chill | 0 (0) | 2 (100) | 4 (14.3) | 24 (85.7) | 1.000 | ||
| Rhinorrhea | 0 (0) | 2 (100) | 5 (17.9) | 23 (82.1) | 1.000 | ||
| Tonsilitis | 1 (50.0) | 1 (50.0) | 8 (28.6) | 20 (71.4) | 0.517 | 2.50 | 0.139–45.01 |
| Headache | 0 (0) | 2 (100.0) | 6 (21.4) | 22 (78.6) | 1.000 | ||
| Body ache | 1 (50.0) | 1 (50.0) | 9 (32.1) | 19 (67.9) | 1.000 | 2.11 | 0.118–37.722 |
| Arthralgia | 0 (0) | 2 (100) | 2 (7.1) | 26 (92.9) | 1.000 | ||
| Dyspnea | 0 (0) | 2 (100) | 0 (0) | 28 (100) | |||
| Chest discomfort | 0 (0) | 2 (100) | 0 (0) | 28 (100) | |||
| Fatigue | 0 (0) | 2 (100) | 1 (3.6) | 27 (96.4) | 1.000 | ||
| General weakness | 0 (0) | 2 (100) | 0 (0) | 28 (100) | |||
| Olfactory sense loss | 1 (50.0) | 1 (50.0) | 1 (3.6) | 27 (96.4) | 0.131 | 27.0 | 0.887–821.79 |
| Nasal obstruction | 0 (0) | 2 (100) | 4 (14.3) | 24 (85.7) | 1.000 | ||
| Taste sense loss | 1 (50.0) | 1 (50.0) | 1 (3.6) | 27 (96.4) | 0.131 | 27.0 | 0.887–821.79 |
| Diarrhea | 1 (50.0) | 1 (50.0) | 3 (10.7) | 25 (89.3) | 0.253 | 8.33 | 0.407–170.66 |
| Hoarse voice | 0 (0) | 2 (100) | 1 (3.6) | 27 (96.4) | 1.000 | ||
*: χ2 test and Fisher’s exact test (p-value < 0.05), **: Mann–Whitney test (p-value < 0.05).
Difference between laboratory results of COVID-19 (+) office cleaners (n = 2) and public officers (n = 18).
| Laboratory Index | Office Cleaner: | Public Officer: | |||
|---|---|---|---|---|---|
| Number of Abnormal Patient(s) * | (Median, Range) | Number of Abnormal Patient(s) * | (Median, Range) | ||
| Upper respiratory PCR ( | |||||
| RdRp(Ct) value | 1/2 (50%) | (34.17, 32.89–35.45) | 23 (100%) * | (24.99, 17.60–33.60) | 0.035 |
| E(Ct) value | 2/2 (100%) | (32.30, 31.91–32.68) | 23 (100%) * | (24.74, 17.20–33.00) | 0.045 |
| Complete blood count ( | |||||
| White blood cell (k/µL) | 0/2 (0%) | (5.95, 4.60–7.30) | 2/18 (11.1%) | (5.50, 3.57–9.37) | 0.705 |
| Neutrophil (%) | 2/2 (100%) | (80.10, 77.30–82.90) | 3/18 (16.7%) | (57.95, 43.60–80.0) | 0.044 |
| Neutrophil count (/µL) | 0/2 (0%) | (4.75, 3.50–6.00) | 1/10 (10.0%) | (3.66, 1.68–6.38) | 0.451 |
| Lymphocyte (%) | 2/2 (100%) | (14.85, 14.30–15.40) | 3/18 (16.7%) | (30.70, 13.0–42.0) | 0.078 |
| Lymphocyte count (/µL) | 1/2 (50%) | (0.85, 0.70–1.00) | 3/10 (30.0%) | (1.62, 0.90–3.09) | 0.086 |
| Eosinophil (%) | 0/2 (0%) | (0.40, 0.3–0.5) | 0/18 (0%) | (1.15, 0–3.70) | 0.114 |
| Eosinophil count (/µL) | 0/2 (0%) | (0) | 0/10 (0%) | (0.07, 0–0.20) | 0.079 |
| Basophil (%) | 0/2 (0%) | (0.15, 0.10–0.20) | 1/18 (5.6%) | (0.4, 0–2.20) | 0.338 |
| Basophil count (/µL) | 0/2 (0%) | (0) | 0/10 (0%) | (0.02, 0–0.10) | 0.118 |
| Monocyte (%) | 1/2 (50%) | (4.50, 2.10–6.90) | 2/18 (11.1%) | (7.0, 5.0–13.0) | 0.183 |
| Monocyte count (/µL) | 1/2 (50%) | (0.25, 0.20–0.30) | 0/10 (0%) | (0.46, 0.30–0.68) | 0.051 |
| Serum chemistry ( | |||||
| Glucose, fasting (mg/dL) | 2/2 (100%) | (163.50, 163–164) | 5/18 (27.8%) | (102.50, 86–188) | 0.044 |
| Blood urea nitrogen (mg/dL) | 0/2 (0%) | (11.1, 10.70–11.50) | 1/18 (5.6%) | (13.10, 7.60–17.50) | 0.378 |
| Serum creatinine (mg/dL) | 2/2 (100%) | (0.67, 0.58–0.75) | 9/18 (50.0%) | (0.88, 0.43–1.24) | 0.207 |
| Proteins, total (g/dL) | 0/2 (0%) | (7.45, 7.30–7.60) | 4/18 (22.3%) | (7.60, 6.30–8.20) | 0.705 |
| Albumin (g/dL) | 1/2 (50%) | (3.70, 3.40–4.00) | 2/18 (11.1%) | (4.20, 3.70–4.70) | 0.049 |
| Serum bilirubin, total (mg/dL) | 0/2 (0%) | (0.49, 0.28–0.69) | 0/18 (0%) | (0.48, 0.28–1.03) | 0.801 |
| Alkaline phosphatase (IU/L) | 0/2 (0%) | (62.50, 54–71) | 8/18 (44.4%) | (72.50, 40–261) | 0.801 |
| Aspartate aminotransferase (IU/L) | 0/2 (0%) | (17, 14–20) | 5/18 (27.8%) | (23.50, 9–49) | 0.207 |
| Alanine aminotransferase (IU/L) | 0/2 (0%) | (16.50, 14–19) | 5/18 (27.8%) | (29.5, 11–78) | 0.115 |
| Lactate dehydrogenase (mg/dL) | 2/2 (100%) | (510, 466–554) | 3/18 (16.7%) | (360, 223–513) | 0.044 |
| Creatine kinase (IU/L) | 0/2 (0%) | (80.50, 76–85) | 3/18 (16.7%) | (96, 39–364) | 0.412 |
| Cholesterol (mg/dL) | 1/2 (50%) | (191, 151–231) | 2/18 (11.1%) | (186, 105–224) | 0.705 |
*: The numbers and rates of patients with abnormal results per patients who took each test (cf. upper respiratory PCR continuous values were acquired from 25 out of 30 COVID-19 patients). **: Mann–Whitney test (p-value < 0.05).
Radiological findings of the COVID-19 (+) participants at admission (n = 18).
| Office Cleaner: | Public Officer: | OR | 95% CI | ||||
|---|---|---|---|---|---|---|---|
| Yes | No | Yes | No | ||||
| Radiological finding of X-ray ( | |||||||
| Pneumonia | 0 (0) | 2 (100) | 3 (18.8) | 13 (81.3) | 1.000 | ||
| Ground glass opacity | 2 (100.0) | 0 (0) | 3 (18.8) | 13 (81.3) | 0.065 | ||
| Consolidation | 0 | 2 (100) | 0 | 16 (100) | |||
| Diffuse pattern | 1 (50.0) | 1 (50.0) | 0 | 16 (100) | 0.111 | ||
| Atelectasis | 1 (50.0) | 1 (50.0) | 1 (6.3) | 15 (93.8) | 0.216 | 15.0 | 0.485–464.20 |
| Emphysema | 0 (0) | 2 (100) | 0 | 16 (100) | |||
| Nodule | 1 (50.0) | 1 (50.0) | 1 (6.3) | 15 (93.8) | 0.216 | 15.0 | 0.485–464.20 |
| Calcification | 0 (0) | 2 (100) | 0 | 16 (100) | |||
| Pleural effusion | 0 (0) | 2 (100) | 0 | 16 (100) | |||
| Invasion lesion of | |||||||
| Right upper lobe | 0 (0) | 2 (100) | 2 (12.5) | 14 (87.5) | 1.000 | ||
| Right middle lobe | 1 (50.0) | 1 (50.0) | 1 (6.3) | 15 (93.8) | 0.216 | 15.0 | 0.485–464.20 |
| Right lower lobe | 1 (50.0) | 1 (50.0) | 3 (18.8) | 13 (81.3) | 0.405 | 4.33 | 0.207–90.85 |
| Left upper lobe | 0 (0) | 2 (100) | 2 (12.5) | 14 (87.5) | 1.000 | ||
| Left lower lobe | 2 (100) | 0 (0) | 4 (25.0) | 12 (75.0) | 0.098 | ||
| Both lobe | 2 (100) | 0 (0) | 2 (12.5) | 14 (87.5) | 0.039 | ||
| Whole | 0 (0) | 2 (100) | 0 | 16 (100) | |||
| Radiological finding of CT ( | |||||||
| Pneumonia | 2 (100) | 0 (0) | 12 (80.0) | 3 (20.0) | 1.000 | ||
| Ground glass opacity | 2 (100.0) | 0 (0) | 11 (73.3) | 4 (26.7) | 1.000 | ||
| Consolidation | 1 (50.0) | 1 (50.0) | 5 (33.0) | 10 (66.7) | 1.000 | 2.0 | 0.102–39.079 |
| Diffuse pattern | 0 (0) | 2 (100) | 0 (0) | 15 (100) | |||
| Atelectasis | 1 (50.0) | 1 (50.0) | 1 (6.7) | 14 (93.3) | 0.228 | 14.0 | 0.451–434.41 |
| Emphysema | 0 (0) | 2 (100) | 1 (6.7) | 14 (93.3) | 1.000 | ||
| Nodule | 0 (00) | 2 (100) | 0 (0) | 15 (100) | |||
| Calcification | 0 (00) | 2 (100) | 0 (0) | 15 (100) | |||
| Pleural effusion | 0 (00) | 2 (100) | 0 (0) | 15 (100) | |||
| Invasion lesion of CT ( | |||||||
| Right upper lobe | 2 (100) | 0 (0) | 7 (46.7) | 8 (53.3) | 0.471 | ||
| Right middle lobe | 2 (100) | 0 (0) | 0 (0) | 15 (100) | 0.007 | ||
| Right lower lobe | 2 (100) | 0 (0) | 5 (33.3) | 10 (66.7) | 0.154 | ||
| Left upper lobe | 2 (100) | 0 (0) | 7 (46.7) | 8 (53.3) | 0.471 | ||
| Left lower lobe | 2 (100) | 0 (0) | 5 (33.3) | 10 (66.7) | 0.154 | ||
| Both lobe | 2 (100) | 0 (0) | 5 (33.3) | 10 (66.7) | 0.154 | ||
| Whole | 2 (100) | 0 (0) | 0 (0) | 15 (100) | 0.007 | ||
| Pneumonia severity | |||||||
| PSI risk class | |||||||
| 1 | 1 (50.0) | 8 (80) | 0.455 | ||||
| 2 | 1 (50.0) | 2 (20) | |||||
| CURB score (Zero) | 0 (0) | 2 (100) | 0 (0) | 13 (100) | |||
* χ2 test and Fisher’s exact test (p-value < 0.05).